The National Institute of Allergy and Infectious Diseases (NIAID) of the Department of Health and Human Services awarded a $6,620,728 cost-plus-fixed-fee contract to Xequel Bio, Inc. (doing business as FSR) to develop a topical therapeutic called GRANEXIN to mitigate cutaneous radiation injury. This contract was awarded under a prior NIAID Broad Agency Announcement that sought proposals for advanced development of medical countermeasures, including those targeting radiation exposure. The contract has a period of performance through February 28, 2025. There was no set-aside designation for this competitive award.
Generated 10/31/24, 10:11 AM